Evidence map›Paper›PMID 26063644›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2015

Expression of serum miR-200a, miR-200b, and miR-200c as candidate biomarkers in epithelial ovarian cancer and their association with clinicopathological features.

M Zuberi, R Mir, J Das, I Ahmad, J Javid, P Yadav, M Masroor, S Ahmad, P C Ray, A Saxena

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 88 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
88citing papers in PubMed, 4 pooled it
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

88 citing papers in PubMed, 4 syntheses or guidelines pooled it, 132 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review

28 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

M ZuberiDepartment of Biochemistry, Maulana Azad Medical College, New Delhi, 110002, India.
R MirPrince Fahd Bin Sultan Research Chair, University of Tabuk, Tabuk, 71491, Saudi Arabia.
J DasDepartment of Biochemistry, Maulana Azad Medical College, New Delhi, 110002, India.
I AhmadDepartment of Biochemistry, Maulana Azad Medical College, New Delhi, 110002, India.
J JavidDepartment of Biochemistry, Maulana Azad Medical College, New Delhi, 110002, India.
P YadavDepartment of Biochemistry, Maulana Azad Medical College, New Delhi, 110002, India.
M MasroorDepartment of Biochemistry, Maulana Azad Medical College, New Delhi, 110002, India.
S AhmadDepartment of Biochemistry, Maulana Azad Medical College, New Delhi, 110002, India.
P C RayDepartment of Biochemistry, Maulana Azad Medical College, New Delhi, 110002, India.
A SaxenaDepartment of Biochemistry, Maulana Azad Medical College, New Delhi, 110002, India. alpanasaxena@hotmail.com.
Maulana Azad Medical College · INFahd bin Sultan University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMicroRNAs (miRs) have been implicated in the etiology of various human cancers. The aim of this study was to investigate the association of the expression of three members--miR 200a, miR 200b, and miR 200c belonging to the miR-200 family with clinicopathological characteristics and their impact on the progression of epithelial ovarian cancer (EOC). MATERIALS AND

methodsTotal RNA from serum was isolated by Trizol method, polyadenylated, and reverse transcribed into cDNA. Expression levels of miR-200a, miR-200b, and miR-200c were detected by using miRNA qRT-PCR. We measured miR expression in 70 serum samples of EOC patients with matched controls using U6 snRNA as a reference. Levels of miR expression was compared with distinct clinicopathological features.

resultsExpression of miR-200a was found to be greater than six-fold (p = 0.01), miR-200b and miR-200c greater than three-fold (p = 0.01) in comparison with matched normal controls. Association of miRNA expression with clinicopathological factors and progression was statistically evaluated. The expression levels of miR-200a and miR-200c were found to be significantly associated with disease progression (p = 0.04 and p < 0.001, respectively). miR-200a overexpression was found be associated with tumor histology and stage. Patients with lymph node metastasis showed significant elevation of miR-200c (p = 0.006). The AUC in ROC curve also indicated that serum levels of miR-200a and miR-200c might be worthwhile as a diagnostic tool in the near future.

conclusionOur findings suggest that miR-200a, miR-200b, and miR-200c overexpressions are associated with the aggressive tumor progression and be recognized as reliable markers to predict the prognosis and survival in EOC patients.

Indexed as

Gene Expression Regulation, NeoplasticAdenocarcinoma, Clear CellAdenocarcinoma, MucinousAdenocarcinoma, PapillaryAdultArea Under CurveBiomarkers, TumorCarcinoma, EndometrioidCarcinoma, Ovarian EpithelialCase-Control StudiesDisease ProgressionFemaleHumansLymphatic MetastasisLymph NodesMicroRNAsBiomarkers, TumorMicroRNAsMIRN200 microRNA, humanBiomarkerDisease progressionOverexpressionqRT-PCR

Identifiers

PMID26063644
OpenAlexW1894771330

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.